829 related articles for article (PubMed ID: 23737439)
1. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement.
Shu R; Bai D; Sheu T; He Y; Yang X; Xue C; He Y; Zhao M; Han X
PLoS One; 2017; 12(1):e0167312. PubMed ID: 28081119
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
5. Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells.
Yokomoto-Umakoshi M; Kanazawa I; Takeno A; Tanaka K; Notsu M; Sugimoto T
Biochem Biophys Res Commun; 2016 Jan; 469(4):791-6. PubMed ID: 26713363
[TBL] [Abstract][Full Text] [Related]
6. Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size.
Kogawa M; Khalid KA; Wijenayaka AR; Ormsby RT; Evdokiou A; Anderson PH; Findlay DM; Atkins GJ
Am J Physiol Cell Physiol; 2018 Jan; 314(1):C53-C61. PubMed ID: 28978523
[TBL] [Abstract][Full Text] [Related]
7. Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis.
Ormsby RT; Cantley M; Kogawa M; Solomon LB; Haynes DR; Findlay DM; Atkins GJ
Acta Biomater; 2016 Mar; 33():242-51. PubMed ID: 26796208
[TBL] [Abstract][Full Text] [Related]
8. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.
Tanaka K; Yamaguchi T; Kanazawa I; Sugimoto T
Biochem Biophys Res Commun; 2015 May; 461(2):193-9. PubMed ID: 25721666
[TBL] [Abstract][Full Text] [Related]
9. Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells.
Notsu M; Kanazawa I; Takeno A; Yokomoto-Umakoshi M; Tanaka KI; Yamaguchi T; Sugimoto T
Calcif Tissue Int; 2017 Apr; 100(4):402-411. PubMed ID: 28229177
[TBL] [Abstract][Full Text] [Related]
10. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
11. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
12. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin
Ma J; Wang A; Zhang H; Liu B; Geng Y; Xu Y; Zuo G; Jia P
Bone; 2022 Nov; 164():116511. PubMed ID: 35933095
[TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium-derived factor (PEDF) reduced expression and synthesis of SOST/sclerostin in bone explant cultures: implication of PEDF-osteocyte gene regulation in vivo.
Li F; Cain JD; Tombran-Tink J; Niyibizi C
J Bone Miner Metab; 2019 Sep; 37(5):773-779. PubMed ID: 30607618
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase III protects osteocytes from oxidative stress.
Shi C; Uda Y; Dedic C; Azab E; Sun N; Hussein AI; Petty CA; Fulzele K; Mitterberger-Vogt MC; Zwerschke W; Pereira R; Wang K; Pajevic PD
FASEB J; 2018 Jan; 32(1):440-452. PubMed ID: 28928248
[TBL] [Abstract][Full Text] [Related]
15. Osteocytes: regulating the mineral reserves?
Arnett TR
J Bone Miner Res; 2013 Dec; 28(12):2433-5. PubMed ID: 24166807
[No Abstract] [Full Text] [Related]
16. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
19. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
20. Human primary osteocyte differentiation in a 3D culture system.
Boukhechba F; Balaguer T; Michiels JF; Ackermann K; Quincey D; Bouler JM; Pyerin W; Carle GF; Rochet N
J Bone Miner Res; 2009 Nov; 24(11):1927-35. PubMed ID: 19419324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
